A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.

Apoptosis Breast Neoplasms / genetics Circadian Clocks Computational Biology Female GTP-Binding Protein alpha Subunits / genetics GTP-Binding Protein alpha Subunits, Gq-G11 / genetics Gene Regulatory Networks Genetic Variation Genome-Wide Association Study Genotype Germ Cells Humans Prognosis Receptors, Estrogen / genetics Signal Transduction

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
16 01 2020
Historique:
received: 31 01 2019
accepted: 17 12 2019
entrez: 18 1 2020
pubmed: 18 1 2020
medline: 9 4 2020
Statut: epublish

Résumé

Identifying the underlying genetic drivers of the heritability of breast cancer prognosis remains elusive. We adapt a network-based approach to handle underpowered complex datasets to provide new insights into the potential function of germline variants in breast cancer prognosis. This network-based analysis studies ~7.3 million variants in 84,457 breast cancer patients in relation to breast cancer survival and confirms the results on 12,381 independent patients. Aggregating the prognostic effects of genetic variants across multiple genes, we identify four gene modules associated with survival in estrogen receptor (ER)-negative and one in ER-positive disease. The modules show biological enrichment for cancer-related processes such as G-alpha signaling, circadian clock, angiogenesis, and Rho-GTPases in apoptosis.

Identifiants

DOI: 10.1038/s41467-019-14100-6 PMID: 31949161 PMC: PMC6965101
pubmed: 31949161
doi: 10.1038/s41467-019-14100-6
pii: 10.1038/s41467-019-14100-6
pmc: PMC6965101
doi:

Substances chimiques

GNA11 protein, human 0
GTP-Binding Protein alpha Subunits 0
Receptors, Estrogen 0
G protein alpha 16 EC 3.6.5.1
GTP-Binding Protein alpha Subunits, Gq-G11 EC 3.6.5.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

312

Subventions

Organisme : NCI NIH HHS
ID : R01 CA176785
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201100004I
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA176726
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100003C
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA092044
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA058223
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA116167
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA128978
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100002C
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148112
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA098758
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148065
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201100002I
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100004C
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA164917
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA199277
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA179715
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA128931
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201100001I
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA156733
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_14105
Pays : United Kingdom
Organisme : NIEHS NIH HHS
ID : P30 ES010126
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA164973
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA164920
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA097396
Pays : United States
Organisme : Cancer Research UK
ID : 29186
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : UM1 CA176726
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201100046C
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA058860
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148537
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA116167
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA177150
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA116201
Pays : United States
Organisme : NIA NIH HHS
ID : HHSN271201100004C
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA063464
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA023100
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA063464
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA077398
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA054281
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA132839
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA058860
Pays : United States
Organisme : Cancer Research UK
ID : 10118
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA192393
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA054281
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100001C
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164973
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA140286
Pays : United States

Références

Lindström, L. S. et al. Prognostic information of a previously diagnosed sister is an independent prognosticator for a newly diagnosed sister with breast cancer. Ann. Oncol. 25, 1966–1972 (2014).
pubmed: 25057175 doi: 10.1093/annonc/mdu270
Verkooijen, H. M. et al. Breast cancer prognosis is inherited independently of patient, tumor and treatment characteristics. Int. J. Cancer 130, 2103–2110 (2012).
pubmed: 21630259 doi: 10.1002/ijc.26206
Michailidou, K. et al. Association analysis identifies 65 new breast cancer risk loci. Nature 551, 92–94 (2017).
pubmed: 29059683 pmcid: 5798588 doi: 10.1038/nature24284
Escala-Garcia, M. et al. Genome-wide association study of germline variants and breast cancer-specific mortality. Br. J. Cancer 120, 647–657 (2019).
pubmed: 30787463 pmcid: 6461853 doi: 10.1038/s41416-019-0393-x
Guo, Q. et al. Identification of novel genetic markers of breast cancer survival. JNCI J. Natl Cancer Inst. 107, djv081–djv081 (2015).
pubmed: 25890600 doi: 10.1093/jnci/djv081
Wang, K., Li, M. & Hakonarson, H. Analysing biological pathways in genome-wide association studies. Nat. Rev. Genet. 11, 843–854 (2010).
pubmed: 21085203 doi: 10.1038/nrg2884
Menashe, I. et al. Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res. 70, 4453–4459 (2010).
pubmed: 20460509 pmcid: 2907250 doi: 10.1158/0008-5472.CAN-09-4502
Baranzini, S. E. et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum. Mol. Genet. 18, 2078–2090 (2009).
pubmed: 19286671 pmcid: 2678928 doi: 10.1093/hmg/ddp120
Luo, L. et al. Genome-wide gene and pathway analysis. Eur. J. Hum. Genet. 18, 1045–1053 (2010).
pubmed: 20442747 pmcid: 2924916 doi: 10.1038/ejhg.2010.62
Leiserson, M. D. M. et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 47, 106–114 (2015).
pubmed: 25501392 doi: 10.1038/ng.3168
Petersen, A., Alvarez, C., DeClaire, S. & Tintle, N. L. Assessing methods for assigning SNPs to genes in gene-based tests of association using common variants. PLoS ONE 8, e62161 (2013).
pubmed: 23741293 pmcid: 3669368 doi: 10.1371/journal.pone.0062161
Lamparter, D., Marbach, D., Rueedi, R., Kutalik, Z. & Bergmann, S. Fast and rigorous computation of gene and pathway scores from SNP-based summary statistics. PLOS Comput. Biol. 12, e1004714 (2016).
pubmed: 26808494 pmcid: 4726509 doi: 10.1371/journal.pcbi.1004714
Marbach, D. et al. Tissue-specific regulatory circuits reveal variable modular perturbations across complex diseases. Nat. Methods 13, 366–370 (2016).
pubmed: 26950747 pmcid: 4967716 doi: 10.1038/nmeth.3799
Azzato, E. M. et al. A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol. Biomark. Prev. 19, 1140–1143 (2010).
doi: 10.1158/1055-9965.EPI-10-0085
Kiyotani, K. et al. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum. Mol. Genet. 21, 1665–1672 (2012).
pubmed: 22180457 doi: 10.1093/hmg/ddr597
Shu, X. O. et al. Novel genetic markers of breast cancer survival identified by a genome-wide association study. Cancer Res. 72, 1182–1189 (2012).
pubmed: 22232737 pmcid: 3294129 doi: 10.1158/0008-5472.CAN-11-2561
Rafiq, S. et al. Identification of inherited genetic variations influencing prognosis in early-onset breast cancer. Cancer Res. 73, 1883–1891 (2013).
pubmed: 23319801 pmcid: 3601979 doi: 10.1158/0008-5472.CAN-12-3377
Han, C. H. et al. Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer. J. Exp. Clin. Cancer Res. 30, 5 (2011).
pubmed: 21214932 pmcid: 3025876 doi: 10.1186/1756-9966-30-5
Lai, J.-P., Sandhu, D. S., Shire, A. M. & Roberts, L. R. The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis. J. Gastrointest. Cancer 39, 149–158 (2008).
pubmed: 19373441 doi: 10.1007/s12029-009-9058-y
Emerson, C. P. et al. QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc. Natl Acad. Sci. 101, 4833–4838 (2004).
pubmed: 15051888 pmcid: 387334 doi: 10.1073/pnas.0401028101
Ai, X. et al. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J. Cell Biol. 162, 341–351 (2003).
pubmed: 12860968 pmcid: 2172803 doi: 10.1083/jcb.200212083
Sebastian, K. et al. Characterization of SLCO5A1/OATP5A1, a solute carrier transport protein with non-classical function. PLoS ONE 8, e83257 (2013).
pubmed: 24376674 pmcid: 3869781 doi: 10.1371/journal.pone.0083257
Cowen, L., Ideker, T., Raphael, B. J. & Sharan, R. Network propagation: a universal amplifier of genetic associations. Nat. Rev. Genet. 18, 551–562 (2017).
pubmed: 28607512 doi: 10.1038/nrg.2017.38
Nakka, P., Raphael, B. J. & Ramachandran, S. Gene and network analysis of common variants reveals novel associations in multiple complex diseases. Genetics 204, 783–798 (2016).
pubmed: 27489002 pmcid: 5068862 doi: 10.1534/genetics.116.188391
Razick, S., Magklaras, G. & Donaldson, I. M. iRefIndex: a consolidated protein interaction database with provenance. BMC Bioinform. 9, 405 (2008).
doi: 10.1186/1471-2105-9-405
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
doi: 10.1038/nature11412
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102
Joshi-Tope, G. et al. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 33, D428–D432 (2005).
pubmed: 15608231 doi: 10.1093/nar/gki072
Liberzon, A. et al. The Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021 pmcid: 4707969 doi: 10.1016/j.cels.2015.12.004
Lappano, R. & Maggiolini, M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov. 10, 47–60 (2011).
pubmed: 21193867 doi: 10.1038/nrd3320
Kisfalvi, K., Rey, O., Young, S. H., Sinnett-Smith, J. & Rozengurt, E. Insulin potentiates Ca2+ signaling and phosphatidylinositol 4,5-bisphosphate hydrolysis induced by Gq protein-coupled receptor agonists through an mTOR-dependent pathway. Endocrinology 148, 3246–3257 (2007).
pubmed: 17379645 doi: 10.1210/en.2006-1711
Sassmann, A. et al. The Gq/G11-mediated signaling pathway is critical for autocrine potentiation of insulin secretion in mice. J. Clin. Invest. 120, 2184–2193 (2010).
pubmed: 20440069 pmcid: 2877950 doi: 10.1172/JCI41541
Imamura, T. et al. G alpha-q/11 protein plays a key role in insulin-induced glucose transport in 3T3-L1 adipocytes. Mol. Cell. Biol. 19, 6765–6774 (1999).
pubmed: 10490615 pmcid: 84673 doi: 10.1128/MCB.19.10.6765
Nierodzik, M. L. & Karpatkin, S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10, 355–362 (2006).
pubmed: 17097558 doi: 10.1016/j.ccr.2006.10.002
Woulfe, D. S. Platelet G protein-coupled receptors in hemostasis and thrombosis. J. Thromb. Haemost. 3, 2193–2200 (2005).
pubmed: 16194198 doi: 10.1111/j.1538-7836.2005.01338.x
Lal, I., Dittus, K. & Holmes, C. E. Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res. 15, 207 (2013).
pubmed: 23905544 pmcid: 3979075 doi: 10.1186/bcr3425
Gaucher, J., Montellier, E. & Sassone-Corsi, P. Molecular cogs: interplay between circadian clock and cell cycle. Trends Cell Biol. 28, 368–379 (2018).
pubmed: 29471986 doi: 10.1016/j.tcb.2018.01.006
Hansen, J. & Stevens, R. G. Case-control study of shift-work and breast cancer risk in Danish nurses: impact of shift systems. Eur. J. Cancer 48, 1722–1729 (2012).
pubmed: 21852111 doi: 10.1016/j.ejca.2011.07.005
Knutsson, A. et al. Breast cancer among shift workers: results of the WOLF longitudinal cohort study. Scand. J. Work. Environ. Health 39, 170–177 (2013).
pubmed: 23007867 doi: 10.5271/sjweh.3323
Travis, R. C. et al. Night shift work and breast cancer incidence: three prospective studies and meta-analysis of published studies. J. Natl Cancer Inst. 108, djw169 (2016).
pubmed: 27758828 pmcid: 5241898 doi: 10.1093/jnci/djw169
Rabstein, S. et al. Night work and breast cancer estrogen receptor status-results from the German GENICA study. Scand. J. Work. Environ. Health 39, 448–455 (2013).
pubmed: 23543199 doi: 10.5271/sjweh.3360
Zienolddiny, S. et al. Analysis of polymorphisms in the circadian-related genes and breast cancer risk in Norwegian nurses working night shifts. Breast Cancer Res. 15, R53 (2013).
pubmed: 23822714 pmcid: 3978690 doi: 10.1186/bcr3445
Reszka, E., Przybek, M., Muurlink, O. & Pepłonska, B. Circadian gene variants and breast cancer. Cancer Lett. 390, 137–145 (2017).
pubmed: 28109907 doi: 10.1016/j.canlet.2017.01.012
Cadenas, C. et al. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle 13, 3282–3291 (2014).
pubmed: 25485508 pmcid: 4613905 doi: 10.4161/15384101.2014.954454
Ha, N.-H., Long, J., Cai, Q., Shu, X. O. & Hunter, K. W. The circadian rhythm gene Arntl2 is a metastasis susceptibility gene for estrogen receptor-negative breast cancer. PLoS Genet. 12, e1006267 (2016).
pubmed: 27656887 pmcid: 5033489 doi: 10.1371/journal.pgen.1006267
Yang, X. et al. The circadian clock gene per1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol. Int. 26, 1323–1339 (2009).
pubmed: 19916834 doi: 10.3109/07420520903431301
Komatsu, N. et al. The circadian gene Per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol. Cell 22, 375–382 (2006).
pubmed: 16678109 doi: 10.1016/j.molcel.2006.03.038
Kuo, S.-J. et al. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26, 1241–1246 (2005).
pubmed: 15790588 doi: 10.1093/carcin/bgi075
Unsal-Kacmaz, K., Mullen, T. E., Kaufmann, W. K. & Sancar, A. Coupling of human circadian and cell cycles by the timeless protein. Mol. Cell. Biol. 25, 3109–3116 (2005).
pubmed: 15798197 pmcid: 1069621 doi: 10.1128/MCB.25.8.3109-3116.2005
Rigaill, G. et al. TIPIN depletion leads to apoptosis in breast cancer cells. Mol. Oncol. 9, 1580–1598 (2015).
pubmed: 26004086 pmcid: 5528799 doi: 10.1016/j.molonc.2015.04.010
Ashcroft, M. et al. Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression. J. Clin. Invest. 122, 600–611 (2012).
pubmed: 22214851 pmcid: 3266784 doi: 10.1172/JCI58780
Zhuang, J. et al. Mitochondrial disulfide relay mediates translocation of p53 and partitions its subcellular activity. Proc. Natl Acad. Sci. 110, 17356–17361 (2013).
pubmed: 24101517 pmcid: 3808663 doi: 10.1073/pnas.1310908110
Sun, Y. et al. Haploinsufficiency in the mitochondrial protein CHCHD4 reduces brain injury in a mouse model of neonatal hypoxia-ischemia. Cell Death Dis. 8, e2781 (2017).
pubmed: 28492551 pmcid: 5520716 doi: 10.1038/cddis.2017.196
Windham, P. F. & Tinsley, H. N. CGMP signaling as a target for the prevention and treatment of breast cancer. Semin. Cancer Biol. 31, 106–110 (2015).
pubmed: 24972142 doi: 10.1016/j.semcancer.2014.06.006
Saravani, R., Karami-Tehrani, F., Hashemi, M., Aghaei, M. & Edalat, R. Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468. Cell Prolif. 45, 199–206 (2012).
pubmed: 22469131 pmcid: 6496613 doi: 10.1111/j.1365-2184.2012.00819.x
Aznar, S. & Lacal, J. C. Rho signals to cell growth and apoptosis. Cancer Lett. 165, 1–10 (2001).
pubmed: 11248412 doi: 10.1016/S0304-3835(01)00412-8
Jilg, C. A. et al. PRK1/PKN1 controls migration and metastasis of androgen-independent prostate cancer cells. Oncotarget 5, 12646–12664 (2014).
pubmed: 25504435 pmcid: 4350344 doi: 10.18632/oncotarget.2653
James, R. G. et al. Protein kinase PKN1 represses Wnt/β-catenin signaling in human melanoma cells. J. Biol. Chem. 288, 34658–34670 (2013).
pubmed: 24114839 pmcid: 3843078 doi: 10.1074/jbc.M113.500314
Dillon, L. & Miller, T. Therapeutic targeting of cancers with loss of PTEN function. Curr. Drug Targets 15, 65–79 (2014).
pubmed: 24387334 pmcid: 4310752 doi: 10.2174/1389450114666140106100909
Garcia-Cao, I. et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149, 49–62 (2012).
pubmed: 22401813 pmcid: 3319228 doi: 10.1016/j.cell.2012.02.030
Chen, L. & Guo, D. The functions of tumor suppressor PTEN in innate and adaptive immunity. Cell. Mol. Immunol. 14, 581–589 (2017).
pubmed: 28603282 pmcid: 5520418 doi: 10.1038/cmi.2017.30
Neo, S. H. et al. Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy. Oncotarget 7, 5483–5494 (2016).
pubmed: 26734838 doi: 10.18632/oncotarget.6794
Hartman, M. et al. Is breast cancer prognosis inherited? Breast Cancer Res. 9, R39 (2007).
pubmed: 17598882 pmcid: 1929105 doi: 10.1186/bcr1737
Möller, S. et al. The heritability of breast cancer among women in the nordic twin study of cancer. Cancer Epidemiol. Biomark. Prev. 25, 145–150 (2016).
doi: 10.1158/1055-9965.EPI-15-0913
Anderson, W. F., Rosenberg, P. S., Prat, A., Perou, C. M. & Sherman, M. E. How many etiological subtypes of breast cancer: two, three, four, or more? J. Natl Cancer Inst. 106, 1–11 (2014).
doi: 10.1093/jnci/dju093
Kao, P. Y. P., Leung, K. H., Chan, L. W. C., Yip, S. P. & Yap, M. K. H. Pathway analysis of complex diseases for GWAS, extending to consider rare variants, multi-omics and interactions. Biochim. Biophys. Acta 1861, 335–353 (2017).
doi: 10.1016/j.bbagen.2016.11.030
Reyna, M. A., Leiserson, M. D. M. & Raphael, B. J. Hierarchical HotNet: identifying hierarchies of altered subnetworks. Bioinformatics 34, i972–i980 (2018).
pubmed: 30423088 pmcid: 6129270 doi: 10.1093/bioinformatics/bty613
Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat. Genet. 45, 353–361 (2013). 361e1-2.
pubmed: 23535729 pmcid: 3771688 doi: 10.1038/ng.2563
1000 Genomes Project Consortium et al. A map of human genome variation from population-scale sequencing. Nature 467, 1061–1073 (2010).
doi: 10.1038/nature09534
Delaneau, O., Marchini, J. & Zagury, J.-F. A linear complexity phasing method for thousands of genomes. Nat. Methods 9, 179–181 (2011).
pubmed: 22138821 doi: 10.1038/nmeth.1785
Howie, B., Marchini, J. & Stephens, M. Genotype imputation with thousands of genomes. G3 (Bethesda) 1, 457–470 (2011).
doi: 10.1534/g3.111.001198
Vandin, F., Clay, P., Upfal, E. & Raphael, B. J. Discovery of mutated subnetworks associated with clinical data in cancer. Pac. Symp. Biocomput. 55–66 (2012).
Vandin, F., Upfal, E. & Raphael, B. J. Algorithms for detecting significantly mutated pathways in cancer. J. Comput. Biol. 18, 507–522 (2011).
pubmed: 21385051 doi: 10.1089/cmb.2010.0265
Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1–22 (2010).
pubmed: 20808728 pmcid: 2929880 doi: 10.18637/jss.v033.i01
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
pubmed: 14597658 pmcid: 403769 doi: 10.1101/gr.1239303
Calderone, A., Castagnoli, L. & Cesareni, G. mentha: a resource for browsing integrated protein-interaction networks. Nat. Methods 10, 690–691 (2013).
pubmed: 23900247 doi: 10.1038/nmeth.2561
Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091–1093 (2009).
pubmed: 19237447 pmcid: 2666812 doi: 10.1093/bioinformatics/btp101
Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 5, e13984 (2010).
pubmed: 21085593 pmcid: 2981572 doi: 10.1371/journal.pone.0013984

Auteurs

Maria Escala-Garcia (M)

Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Jean Abraham (J)

Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Cambridge Experimental Cancer Medicine Centre, Cambridge, UK.
Cambridge Breast Unit and NIHR Cambridge Biomedical Research Centre, University of Cambridge NHS Foundation Hospitals, Cambridge, UK.

Irene L Andrulis (IL)

Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
Department of Molecular Genetics, University of Toronto, Toronto, Canada.
ORCID: 0000-0002-4226-6435

Hoda Anton-Culver (H)

Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.

Volker Arndt (V)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID: 0000-0001-9320-8684

Alan Ashworth (A)

UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

Paul L Auer (PL)

Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.

Päivi Auvinen (P)

Cancer Center, Kuopio University Hospital, Kuopio, Finland.
Institute of Clinical Medicine, Oncology, University of Eastern Finland, Kuopio, Finland.
Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.

Matthias W Beckmann (MW)

Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.

Jonathan Beesley (J)

Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Sabine Behrens (S)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Javier Benitez (J)

Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.

Marina Bermisheva (M)

Institute of Biochemistry and Genetics, Ufa Scientific Center of Russian Academy of Sciences, Ufa, Russia.

Carl Blomqvist (C)

Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Department of Oncology, Örebro University Hospital, Örebro, Sweden.

William Blot (W)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
International Epidemiology Institute, Rockville, MD, USA.

Natalia V Bogdanova (NV)

Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.

Stig E Bojesen (SE)

Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID: 0000-0002-4061-4133

Manjeet K Bolla (MK)

Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.

Anne-Lise Børresen-Dale (AL)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

Hiltrud Brauch (H)

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
iFIT-Cluster of Excellence, University of Tuebingen, Tuebingen, Germany.
German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
ORCID: 0000-0001-7531-2736

Hermann Brenner (H)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.

Sara Y Brucker (SY)

Department of Gynecology and Obstetrics, University of Tübingen, Tübingen, Germany.

Barbara Burwinkel (B)

Molecular Epidemiology Group, C080, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Molecular Biology of Breast Cancer, University Womens Clinic Heidelberg, University of Heidelberg, Heidelberg, Germany.

Carlos Caldas (C)

Cancer Research UK Cambridge Institute, Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
Breast Cancer Programme, CRUK Cambridge Cancer Centre and NIHR Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
ORCID: 0000-0003-3547-1489

Federico Canzian (F)

Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID: 0000-0002-4261-4583

Jenny Chang-Claude (J)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Stephen J Chanock (SJ)

Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0002-2324-3393

Suet-Feung Chin (SF)

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
ORCID: 0000-0001-5697-1082

Christine L Clarke (CL)

Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia.

Fergus J Couch (FJ)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Angela Cox (A)

Department of Oncology and Metabolism, Sheffield Institute for Nucleic Acids (SInFoNiA), University of Sheffield, Sheffield, UK.

Simon S Cross (SS)

Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, UK.

Kamila Czene (K)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Mary B Daly (MB)

Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.

Joe Dennis (J)

Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
ORCID: 0000-0003-4591-1214

Peter Devilee (P)

Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
ORCID: 0000-0002-8023-2009

Janet A Dunn (JA)

Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.

Alison M Dunning (AM)

Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
ORCID: 0000-0001-6651-7166

Miriam Dwek (M)

Department of Biomedical Sciences, Faculty of Science and Technology, University of Westminster, London, UK.
ORCID: 0000-0001-7184-2932

Helena M Earl (HM)

Cambridge Breast Unit and NIHR Cambridge Biomedical Research Centre, University of Cambridge NHS Foundation Hospitals, Cambridge, UK.
Department of Oncology, University of Cambridge, Cambridge, UK.

Diana M Eccles (DM)

Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.

A Heather Eliassen (AH)

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Carolina Ellberg (C)

Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden.
ORCID: 0000-0001-7297-0645

D Gareth Evans (DG)

Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Genomic Medicine, St Mary's Hospital, Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK.

Peter A Fasching (PA)

Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
ORCID: 0000-0003-4885-8471

Jonine Figueroa (J)

Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh, UK.
Cancer Research UK Edinburgh Centre, Edinburgh, UK.

Henrik Flyger (H)

Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.

Manuela Gago-Dominguez (M)

Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.
Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.

Susan M Gapstur (SM)

Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.

Montserrat García-Closas (M)

Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
ORCID: 0000-0003-1033-2650

José A García-Sáenz (JA)

Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
ORCID: 0000-0001-6880-0301

Mia M Gaudet (MM)

Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.

Angela George (A)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Graham G Giles (GG)

Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
ORCID: 0000-0003-4946-9099

David E Goldgar (DE)

Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.

Anna González-Neira (A)

Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Mervi Grip (M)

Department of Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland.

Pascal Guénel (P)

Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), University Paris-Saclay, INSERM, University Paris-Sud, Villejuif, France.
ORCID: 0000-0002-8359-518X

Qi Guo (Q)

Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Christopher A Haiman (CA)

Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Niclas Håkansson (N)

Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
ORCID: 0000-0001-7673-5554

Ute Hamann (U)

Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Patricia A Harrington (PA)

Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.

Louise Hiller (L)

Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.

Maartje J Hooning (MJ)

Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

John L Hopper (JL)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.

Anthony Howell (A)

Division of Cancer Sciences, University of Manchester, Manchester, UK.

Chiun-Sheng Huang (CS)

Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

Guanmengqian Huang (G)

Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.

David J Hunter (DJ)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Anna Jakubowska (A)

Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland.

Esther M John (EM)

Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.

Rudolf Kaaks (R)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Pooja Middha Kapoor (PM)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Medicine, University of Heidelberg, Heidelberg, Germany.
ORCID: 0000-0001-5503-8215

Renske Keeman (R)

Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
ORCID: 0000-0002-5452-9933

Cari M Kitahara (CM)

Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.

Linetta B Koppert (LB)

Department of Surgical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Peter Kraft (P)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
ORCID: 0000-0002-4472-8103

Vessela N Kristensen (VN)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

Diether Lambrechts (D)

VIB, VIB Center for Cancer Biology, Leuven, Belgium.
Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium.
ORCID: 0000-0002-3429-302X

Loic Le Marchand (L)

Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.

Flavio Lejbkowicz (F)

Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, Israel.

Annika Lindblom (A)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.

Jan Lubiński (J)

Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.

Arto Mannermaa (A)

Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland.
Department of Clinical Pathology, Imaging Center, Kuopio University Hospital, Kuopio, Finland.

Mehdi Manoochehri (M)

Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Siranoush Manoukian (S)

Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (INT), Milan, Italy.

Sara Margolin (S)

Department of Oncology, Sšdersjukhuset, Stockholm, Sweden.
Department of Clinical Science and Education, Sšdersjukhuset, Karolinska Institutet, Stockholm, Sweden.

Maria Elena Martinez (ME)

Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA.

Tabea Maurer (T)

Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Dimitrios Mavroudis (D)

Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Greece.

Alfons Meindl (A)

Department of Gynecology and Obstetrics, Ludwig Maximilian University of Munich, Munich, Germany.

Roger L Milne (RL)

Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
ORCID: 0000-0001-5764-7268

Anna Marie Mulligan (AM)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.

Susan L Neuhausen (SL)

Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.

Heli Nevanlinna (H)

Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0002-0916-2976

William G Newman (WG)

Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Genomic Medicine, St Mary's Hospital, Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
ORCID: 0000-0002-6382-4678

Andrew F Olshan (AF)

Department of Epidemiology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Janet E Olson (JE)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
ORCID: 0000-0003-4944-7789

Håkan Olsson (H)

Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden.

Nick Orr (N)

Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Ireland, UK.
ORCID: 0000-0003-2866-942X

Paolo Peterlongo (P)

Genome Diagnostics Program, IFOM - the FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy.
ORCID: 0000-0001-6951-6855

Christos Petridis (C)

Research Oncology, Guy's Hospital, King's College London, London, UK.

Ross L Prentice (RL)

Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Nadege Presneau (N)

Department of Biomedical Sciences, Faculty of Science and Technology, University of Westminster, London, UK.

Kevin Punie (K)

Department of Oncology, Leuven Multidisciplinary Breast Center, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
ORCID: 0000-0002-1162-7963

Dhanya Ramachandran (D)

Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
ORCID: 0000-0001-8139-7799

Gad Rennert (G)

Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, Israel.
ORCID: 0000-0002-8512-068X

Atocha Romero (A)

Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
ORCID: 0000-0002-1634-7397

Mythily Sachchithananthan (M)

Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia.

Emmanouil Saloustros (E)

Department of Oncology, University Hospital of Larissa, Larissa, Greece.
ORCID: 0000-0002-0485-0120

Elinor J Sawyer (EJ)

Research Oncology, Guy's Hospital, King's College London, London, UK.

Rita K Schmutzler (RK)

Center for Hereditary Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany.
Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.

Lukas Schwentner (L)

Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany.

Christopher Scott (C)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
ORCID: 0000-0003-1340-0647

Jacques Simard (J)

Genomics Center, Research Center, Centre Hospitalier Universitaire de Québec - Université Laval, Québec City, QC, Canada.
ORCID: 0000-0001-6906-3390

Christof Sohn (C)

National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.

Melissa C Southey (MC)

Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, Australia.

Anthony J Swerdlow (AJ)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.

Rulla M Tamimi (RM)

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

William J Tapper (WJ)

Faculty of Medicine, University of Southampton, Southampton, UK.

Manuel R Teixeira (MR)

Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.
Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
ORCID: 0000-0002-4896-5982

Mary Beth Terry (MB)

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.

Heather Thorne (H)

Peter MacCallum Cancer Center, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.

Rob A E M Tollenaar (RAEM)

Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.

Ian Tomlinson (I)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
ORCID: 0000-0003-3037-1470

Melissa A Troester (MA)

Department of Epidemiology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Thérèse Truong (T)

Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), University Paris-Saclay, INSERM, University Paris-Sud, Villejuif, France.
ORCID: 0000-0002-2943-6786

Clare Turnbull (C)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Celine M Vachon (CM)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Lizet E van der Kolk (LE)

Family Cancer Clinic, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Qin Wang (Q)

Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.

Robert Winqvist (R)

Biocenter Oulu, Cancer and Translational Medicine Research Unit, Laboratory of Cancer Genetics and Tumor Biology, University of Oulu, Oulu, Finland.
Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre Oulu, Oulu, Finland.
ORCID: 0000-0003-0932-9104

Alicja Wolk (A)

Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0001-7387-6845

Xiaohong R Yang (XR)

Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Argyrios Ziogas (A)

Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
ORCID: 0000-0003-4529-3727

Paul D P Pharoah (PDP)

Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
ORCID: 0000-0001-8494-732X

Per Hall (P)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Oncology, Sšdersjukhuset, Stockholm, Sweden.

Lodewyk F A Wessels (LFA)

Division of Molecular Carcinogenesis, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Faculty of EEMCS, Delft University of Technology, Delft, The Netherlands.

Georgia Chenevix-Trench (G)

Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Gary D Bader (GD)

Department of Molecular Genetics, University of Toronto, Toronto, Canada.
The Donnelly Centre, University of Toronto, Toronto, ON, Canada.
ORCID: 0000-0003-0185-8861

Thilo Dörk (T)

Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
ORCID: 0000-0002-9458-0282

Douglas F Easton (DF)

Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
ORCID: 0000-0003-2444-3247

Sander Canisius (S)

Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. s.canisius@nki.nl.
Division of Molecular Carcinogenesis, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. s.canisius@nki.nl.
ORCID: 0000-0003-3888-8829

Marjanka K Schmidt (MK)

Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. mk.schmidt@nki.nl.
Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. mk.schmidt@nki.nl.
ORCID: 0000-0002-2228-429X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › A network analysis to identify mediators of...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › A network analysis to identify mediators of...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes chronobiologiques › Périodicité › Horloges biologiques › Horloges circadiennes › A network analysis to identify mediators of...
questionsmedicales.fr › Sciences de l'information › Informatique › Biologie informatique › A network analysis to identify mediators of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines G hétérotrimériques › Sous-unités alpha des protéines G › A network analysis to identify mediators of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines G hétérotrimériques › Sous-unités alpha des protéines G › Sous-unités alpha Gq-G11 des protéines G › A network analysis to identify mediators of...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Séquences d'acides nucléiques régulatrices › Réseaux de régulation génique › A network analysis to identify mediators of...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › A network analysis to identify mediators of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Épidémiologie moléculaire › Étude d'association pangénomique › A network analysis to identify mediators of...
questionsmedicales.fr › Phénomènes génétiques › Génotype › A network analysis to identify mediators of...
questionsmedicales.fr › Cellules › Cellules germinales › A network analysis to identify mediators of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A network analysis to identify mediators of...
questionsmedicales.fr › Diagnostic › Pronostic › A network analysis to identify mediators of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Récepteurs aux stéroïdes › Récepteurs des oestrogènes › A network analysis to identify mediators of...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › A network analysis to identify mediators of...